Marketed by: MedImmune (Gaithersburg, MD)
Indication: MedImmune announced the FDA approval of FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for the prevention of influenza infection. The first quadrivalent vaccine approved by the FDA, FluMist Quadrivalent contains 4 strains of influenza, with 2 strains each of types A and B. It is approved for patients aged 2 to 49 years. Each intranasal sprayer contains 0.2 mL; 0.1 mL is administered into each nostril. FluMist Quadrivalent will be available starting with the 2013-2014 flu season.
Dosage Form: Intranasal spray: each 0.2- mL dose is supplied in a single-dose, prefilled intranasal sprayer.
For More Information: www.flumistquadrivalent.com
VitaMedMD RediChew RX
Marketed by: TherapeuticsMD, Inc (Boca Raton, FL)
Indication: TherapeuticsMD, Inc announced the launch of vitaMedMD RediChew Rx, a prescription prenatal vitamin for women planning a pregnancy and pregnant women who have difficulty swallowing tablets or capsules. Each vanilla-flavored, chewable tablet is taken once daily and contains 1 mg of a proprietary form of folate, 400 IU of vitamin D3 , 1.7 mg of vitamin B 2 , 2 mg of vitamin B 6 , and 8 mcg of vitamin B 12 . VitaMedMD RediChew Rx is available by prescription through chain, independent, and mail order pharmacies.
Dosage Form: Chewable tablets: 30-count package
For More Information: www.vitamedmdrx.com
Marketed by: Novo Nordisk (Princeton, NJ)
Indication: Novo Nordisk announced the FDA approval of an expansion of Levemir’s (insulin detemir [rDNA origin] injection) indication to include use in children aged 2 to 5 years with type 1 diabetes. It is the first and only basal insulin analog for use in this population. Levemir is administered either twice daily in divided doses or once daily with the evening meal or at bedtime. It is not recommended for treating diabetic ketoacidosis.
Dosage Form: Solution for injection: 100 units/mL in a 3-mL FlexPen or 10-mL vial.
For More Information: www.levemir.com
Fabior Foam, 0.1%
Marketed by: Stiefel, a GSK Company (Research Triangle Park, NC)
Indication: The FDA approved Fabior (tazarotene) Foam, 0.1%, a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years or older. Patients should apply a thin layer of Fabior Foam once daily in the evening to the entire affected area of the face and/or upper trunk, avoiding the eyes, lips, and mucous membranes. After application, patients should wash their hands. Because it contains tazarotene, a teratogenic substance, Fabior Foam is contraindicated during pregnancy.
Dosage Form: Foam for topical use: 0.1%.
For More Information: www.stiefel.com